Aslı HAPA, Nilda SÜSLÜ, Ayşen KARADUMAN, Bilgehan BUDAK, Sibel ERSOY EVANS, Levent SENNAROĞLU

Psoriasis hastalarında işitmenin hastalığın şiddetine göre değerlendirilmesi

Objective: Nowadays, psoriasis is accepted to be an autoinflammatory/autoimmune disease. As a result of chronic inflammation, psoriasis is widely investigated for associated diseases and comorbidities. However, there are limited data about the effects of psoriasis on hearing functions. The aim of the study was to investigate prospectively if patients withpsoriasis have sensorineural hearing loss and the effect of the disease severity on hearing levels.Methods: Overall, 50 patients (100 ears) with psoriasis and 45 healthy controls (90 ears) were included in the study. After otoscopic examination, pure tone air and bone conduction including high frequencies (500, 1000, 2000, 4000, 8000, and 16,000 Hz) and speech audiometry were performed to all participants.Results: Median pure tone average of the patients was significantly different than controls. Moreover, the frequency levels of patients with psoriasis for both of the ears were all significantly different from the control group. As the limitation of the study, patients were not investigated for psoriatic arthritis and sera from patients were also not investigated for anti-bodies for inner ear antigens such as anti-connexin 26, anti-DEP/CD148 and anti 68K.Conclusion: The possibility of inner ear involvement should be kept in mind in psoriasis as a result of chronic systemic inflammation. Patients with psoriasis may be evaluated with audiometry periodically even if they do not exhibit any hearing problems.

Keywords:

Psoriasis, hastalık şiddeti, işitme kaybı, hearing loss, disease severity,

PDF

___

1. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010;23:114–8.
2. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwain. J Dermatol Sci 2011;63:40–6.
3. Zheng Y, Danilenko DM, Valdes P, et al. Interleukin-22, a T(H)17 cytokine mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007,445:648–51.
4. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th-17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159:1092– 102.
5. Hsu LN, Armstrong AW. Psoriasis and autoimmune disorders: a review of the literature. J Am Acad Dermatol 2012;67:1076–9.
6. McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979;88:585–9.
7. Ozturk A, Yalcin S, Kaygusuz I, et al. High-frequency hearing loss and middle ear involvement in rheumatoid arthritis. Am J Otolaryngol 2004;25:411–7.
8. Ery›lmaz A, Dagl› M, Karabulut H, Acar FS, Inal EE, Gocer C. Evalution of hearing loss in patients with ankylosing spondylitis. J Larnygol Otol 2007;121:845–9.
9. Suslu EM, Polat M, Koybas› S, Bicer YO, Funda YO, Parlak AH. Inner ear involvement in Behçet’s disease. Auris Nasus Larynx 2010;37:286–90.
10. Karabulut H, Karadag AS, Dagl› M, Acar B, Babademez MA, Sahin Y, et al. Investigation of hearing and outer hair cell function of cochlea in patients with psoriasis. J Int Adv Otol 2010;6:239–44.
11. Guvenc SC, Turan H, Y›lmaz S, Yan›k ME, Berada A, Alia¤ao¤lu C. Assesment of hearing loss in patients with psoriasis. Turkderm 2012;46:15–9.
12. Giani T, Simonini G, Lunardi C, Puccetti A, Martino M De, Falcini F. Juvenile psoriatic arthritis and acquired sensorineural hearing loss in a teenager: is there an association? Clin Exp Rheumatol 2006;24:344–6.
13. Srikumar S, Deepak MK, Basu K, Kumar BN. Sensorineural hearing loss associated with psoriatic arthritis. J Laryngol Otol 2004;118:909–11.
14. Bloch DB, San Martin JE, Rauch SD, Moscicki RA, Bloch KJ. Serum antibodies to heat shock protein 70 in sensorineurol hear loss. Arch Otolaryngol Head Neck Surg 1995,121:1167–71.
15. Dornhoffer JL, Arenberg IK. Immune mechanisms in Meniere’s disease. Otolaryngol Clin North Am 1997;30:1017–26.
16. Lowes MA, Kikuchi T, Fuentes- Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008,128:1207–11.